EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027

EyePoint, Inc.

First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.
DURAVYU is a sustained-release TKI inhibiting VEGF, PDGF, and IL-6; design based on positive Phase 2 VERONA results.
Non-inferiority trials vs aflibercept; ~240 patients each; primary endpoint BCVA change at weeks 52 and 56.
DURAVYU 2.7mg administered via standard intravitreal injection every six months; topline data anticipated 2H 2027.
Program aligns with FDA and EMA after End of Phase 2 meeting; aims to reduce treatment burden for DME patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.